Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination product containing three components: - **PRF** (likely "poloxamer 188," also known as Pluronic F68): a nonionic surfactant and excipient used in pharmaceutical formulations for its membrane-protective, solubilizing, and emulsifying properties. It has demonstrated potential therapeutic effects in cell membrane repair and neuroprotection, as well as applications in burn wound management[1][2][3][4][5][7]. - **PHMB** (polyhexamethylene biguanide): an antimicrobial polymer widely used for its broad-spectrum antibacterial activity. It is commonly found in wound care products, disinfectants, and contact lens solutions. - **Macrogol** (polyethylene glycol/PEG): an osmotic laxative used to treat constipation by increasing water content in the stool. It is also employed as an excipient to enhance drug solubility and stability[6][8]. The combination of these agents suggests use in topical or wound care settings—PRF for tissue protection/healing support, PHMB for infection control, and macrogol for moisture retention or formulation purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PRF + polyhexamethylene biguanide + macrogol.